Loading…
Intensity Therapeutics, Inc. is projected to rise to $5.52 by 2027, a +15% move from its current price of $4.78. INTS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.64 | $4.78 | $4.92 | -0.06% |
| Jul 14 | $4.58 | $4.77 | $4.97 | -0.12% |
| Jul 15 | $4.54 | $4.77 | $5.01 | -0.18% |
| Jul 16 | $4.50 | $4.77 | $5.05 | -0.24% |
| Jul 17 | $4.47 | $4.77 | $5.08 | -0.30% |
| Jul 18 | $4.44 | $4.76 | $5.11 | -0.36% |
| Jul 19 | $4.41 | $4.76 | $5.14 | -0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.41 | $4.76 | $5.14 | -0.42% |
| Week 2 | $4.26 | $4.74 | $5.28 | -0.84% |
| Week 3 | $4.14 | $4.72 | $5.38 | -1.26% |
| Week 4 | $4.04 | $4.70 | $5.47 | -1.68% |
| Week 5 | $3.95 | $4.68 | $5.55 | -2.10% |
| Week 6 | $3.87 | $4.66 | $5.61 | -2.51% |
| Week 7 | $3.80 | $4.64 | $5.67 | -2.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.
Its lead product candidate INT230-6 is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. (INTS) is trading with a current price of $4.90. The stock has a market capitalization of $13.24M and is ranked 5045 by market measures.
The price outlook sits modest near term, with a 30-day range of $4.02 to $5.98, and a near-term resistance at $4.90 and support at $3.62.
Technical context shows NEUTRAL sentiment, RSI14 at 70, SMA50 at $4.44, SMA200 at $7.55, and an annualized volatility of 60%.
A major floor 34.2% below — a decisive break under it would weaken the trend.
The nearest floor, 24.3% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 66.3% above — clearing it would confirm fresh momentum.
Key INTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.78 | Buy | $4.72 | Buy |
| MA 10 | $4.45 | Buy | $4.53 | Buy |
| MA 20 | $4.16 | Buy | $4.36 | Buy |
| MA 50 | $4.43 | Buy | $4.60 | Buy |
| MA 100 | $5.33 | Sell | $5.57 | Sell |
| MA 200 | $7.54 | Sell | $9.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.77 | Neutral |
| Stoch RSI (14) | 79.81 | Neutral |
| CCI (20) | 130.27 | Buy |
| Williams %R (14) | -13.33 | Info |
| MACD (12,26,9) | 0.13 | Buy |
| ROC (12) | 19.50 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 86.67 | Sell |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | 0.60 | Buy |
| Ultimate (7,14,28) | 81.45 | Sell |
| Momentum (10) | 0.70 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 5.04 | Sell |
| ADX (14) | 30.98 | Buy |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 70, with price trading near established levels. Key moving averages are SMA50 at $4.44 and SMA200 at $7.55, with price action contained within a $4.02 to $5.98 30-day range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.62 | $4.78 | $5.44 | 0% | Neutral | |
| $4.37 | $5.52 | $7.38 | +15% | Neutral | |
| $4.37 | $5.68 | $7.89 | +19% | Neutral | |
| $4.08 | $5.44 | $7.80 | +14% | Neutral | |
| $4.02 | $5.48 | $8.05 | +15% | Neutral | |
| $3.70 | $5.14 | $7.72 | +7% | Neutral | |
| $3.89 | $5.50 | $8.43 | +15% | Neutral | |
| $4.41 | $6.35 | $9.91 | +33% | Bullish | |
| $4.60 | $6.73 | $10.68 | +41% | Bullish | |
| $4.76 | $7.08 | $11.40 | +48% | Bullish | |
| $5.93 | $9.46 | $16.25 | +98% | Bullish | |
| $6.71 | $12.13 | $22.84 | +154% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.62 | $4.78 | $5.67 | +0.00% |
| August 2026 | $3.85 | $4.55 | $5.53 | -4.87% |
| September 2026 | $3.80 | $4.52 | $5.56 | -0.53% |
| October 2026 | $3.82 | $4.58 | $5.68 | +1.20% |
| November 2026 | $3.67 | $4.42 | $5.54 | -3.34% |
| December 2026 | $3.56 | $4.32 | $5.44 | -2.48% |
Click any year to see its month-by-month INTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INTS price prediction for 2026 points to an average of $4.78 (low $3.62, high $5.44) — a potential gain of 0% on today's $4.78. A consolidation phase looks the most probable path here.
In 2027, INTS is projected to trade between $4.37 and $7.38, averaging $5.52 — a potential gain of +15% from today's $4.78. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
Intensity Therapeutics, Inc.'s 2028 outlook centres on $5.68, within a $4.37 to $7.89 range. That is up +3% on the projected 2027 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, INTS could reach as high as $7.80, with a base case around $5.44 and support toward $4.08 — roughly +14% from $4.78. Price action looks broadly range-bound.
Expect INTS to range from $4.02 to $8.05 through 2030. The $5.48 average target implies a +15% move from current prices. That is up +1% on the projected 2029 average. A consolidation phase looks the most probable path here.
The INTS price prediction for 2031 points to an average of $5.14 (low $3.70, high $7.72) — a potential gain of +7% on today's $4.78. Price action looks broadly range-bound.
In 2032, INTS is projected to trade between $3.89 and $8.43, averaging $5.50 — a potential gain of +15% from today's $4.78. That is up +7% on the projected 2031 average. A consolidation phase looks the most probable path here.
Intensity Therapeutics, Inc.'s 2033 outlook centres on $6.35, within a $4.41 to $9.91 range. That is up +15% on the projected 2032 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2034, INTS could reach as high as $10.68, with a base case around $6.73 and support toward $4.60 — roughly +41% from $4.78. Buyers look set to stay in control over this stretch.
Expect INTS to range from $4.76 to $11.40 through 2035. The $7.08 average target implies a +48% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The INTS price prediction for 2040 points to an average of $9.46 (low $5.93, high $16.25) — a potential gain of +98% on today's $4.78. Buyers look set to stay in control over this stretch.
In 2050, INTS is projected to trade between $6.71 and $22.84, averaging $12.13 — a potential gain of +154% from today's $4.78. That is up +28% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INTS today (≈ 209.205021 INTS) could be worth
$2,536.88
+$1,536.88 (+154%) by 2050 · US Dollar
Based on the average projected INTS price of $12.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INTSwould be worth at today's price.
$1,000 invested in INTS on Jul 10, 2025 (≈ 126.582277 INTS) would be worth
$605.06
-$394.94 (-39.5%) today · 0.61× · US Dollar
Based on a INTS entry price of $7.9 vs. today's $4.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.24 | $1,127.36 | +12.7% |
| 1 month ago | $3.74 | $1,278.07 | +27.8% |
| 3 months ago | $5.5 | $869.09 | -13.1% |
| 6 months ago | $10.3 | $464.08 | -53.6% |
| 1 year ago | $7.9 | $605.06 | -39.5% |
| All time (3.0y) ago | $149 | $32.08 | -96.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INTS forecast.
Our base-case forecast reaches $9.60 around 2050.
Implied market cap at $9.60: $25.95M
The multi-year forecast shows a path of gradual upside. In 2026 the min value is $3.62, the avg is $4.90 and the max is $5.57, with ROI 0 and sentiment NEUTRAL.
From 2027 to 2032 the forecast shows modest gains: 2027 avg $5.71 (ROI 16.4%), 2028 avg $5.84 (ROI 19.2%), 2029 avg $5.59 (ROI 14%), 2030 avg $5.63 (ROI 15%), 2031 avg $5.24 (ROI 6.9%), 2032 avg $5.63 (ROI 14.9%).
Starting 2033, sentiment shifts to BULLISH with stronger upside: 2033 avg $6.55 (max $10.35, ROI 33.6%), 2034 avg $6.92 (max $11.12, ROI 41.1%), 2035 avg $7.30 (max $11.92, ROI 49%).
Further out, 2040 is projected at avg $9.75 (max $17.01, ROI 98.9%), and 2050 at avg $12.36 (max $23.74, ROI 152.3%). These are estimates, not guarantees, and the forecast includes both NEUTRAL and BULLISH periods with associated risks.
Tap a question to reveal the answer.
2030 min $4.10, avg $5.63, max $8.37; ROI 15; sentiment NEUTRAL.
Near term shows a neutral stance with 2026 avg $4.90 and ROI 0%. Longer term, 2033 onward is BULLISH with higher upside, including 2050 avg $12.36 and ROI 152.3%.
Yes, the forecast lists 2033 max $10.35 (avg $6.55; ROI 33.6%), indicating potential to exceed $10 in 2033 under the model's assumptions.
Current price is $4.90; the 30-day range is $4.02 to $5.98.
2050 min $6.64, avg $12.36, max $23.74; ROI 152.3%; sentiment BULLISH.
Intensity Therapeutics, Inc. Community Discussion
0Share your Intensity Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.